Adjunctive α2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission

International Journal of Neuropsychopharmacology

Volumn 13, Issue 7, 2010, Pages 891-903

  Marcus, Monica M ^a   Wiker, Charlotte ^a   Frnberg, Olivia ^a   Konradsson Geuken, Åsa ^a   Langlois, Xavier ^b   Jardemark, Kent ^a   Svensson, Torgny H ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

2 adrenoceptor; dopamine; glutamate; receptor occupancy; schizophrenia

Indexed keywords

DOPAMINE; IDAZOXAN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RISPERIDONE; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; AMINO ACID RECEPTOR AFFECTING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; AVOIDANCE BEHAVIOR; BRAIN CORTEX; CATALEPSY; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DOPAMINERGIC ACTIVITY; DRUG EFFECT; DRUG MECHANISM; ELECTROPHYSIOLOGY; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MICRODIALYSIS; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; METABOLISM; SPRAGUE DAWLEY RAT; SYNAPTIC TRANSMISSION; WISTAR RAT;

ADRENERGIC ALPHA-2 RECEPTOR ANTAGONISTS; ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; CATALEPSY; CEREBRAL CORTEX; DOPAMINE AGONISTS; ELECTROPHYSIOLOGICAL PROCESSES; EXCITATORY AMINO ACID AGENTS; IDAZOXAN; MALE; MICRODIALYSIS; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE; RISPERIDONE; SYNAPTIC TRANSMISSION;

EID: 77957241598     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145709990794     Document Type: Article

References (78)

1. Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, et al. (2002). Prefrontal dopamine d1 receptors and working memory in schizophrenia. Journal of Neuroscience 22, 3708-3719. (Pubitemid 37465776)
2. Abi-Dargham A, Moore H (2003). Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist 9, 404-416. (Pubitemid 37204344)
3. Ahlenius S, Hillegaart V (1986). Involvement of extrapyramidal motor mechanisms in the suppression of locomotor activity by antipsychotic drugs: a comparison between the effects produced by pre- and post-synaptic inhibition of dopaminergic neurotransmission. Pharmacology, Biochemistry, and Behavior 24, 1409-1415. (Pubitemid 16067429)
4. Andersson JL, Nomikos GG, Marcus M, Hertel P, et al. (1995). Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectivity in the mesolimbic dopaminergic system. Naunyn Schmiedebergs Archives of Pharmacology 352, 374-385.
5. Arvanov VL, Liang X, Schwartz J, Grossman S, Wang RY (1997). Clozapine and haloperidol modulate N-methyl-Daspartate- and non-N-methyl-D-aspartate receptormediated neurotransmission in rat prefrontal cortical neurons in vitro. Journal of Pharmacology and Experimental Therapeutics 283, 226-234. (Pubitemid 27438966)
6. Ashby Jr. CR, Wang RY (1996). Pharmacological actions of the atypical antipsychotic drug clozapine: a review. Synapse 24, 349-394.
7. Aura J, Riekkinen Jr. P (1999). Blockade of NMDA receptors located at the dorsomedial prefrontal cortex impairs spatial working memory in rats. Neuroreport 10, 243-248. (Pubitemid 29104794)
8. Beneyto M, Meador-Woodruff JH (2008). Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder. Neuropsychopharmacology 33, 2175-2186. (Pubitemid 351992080)
9. Carpenter Jr. WT (1996). The treatment of negative symptoms: pharmacological and methodological issues. British Journal of Psychiatry (Suppl.) 29, 17-22. (Pubitemid 26181863)
10. Coyle JT, Tsai G, Goff D (2003). Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Annals of the New York Academy of Sciences 1003, 318-327. (Pubitemid 38083065)
11. Davies LM, Barnes TR, Jones PB, Lewis S, et al. (2008). A randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine. Value in Health 11, 549-562. (Pubitemid 352032801)
12. Davis JM, Chen N, Glick ID (2003). A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry 60, 553-564. (Pubitemid 36682312)
13. de Boer T (1995). The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. International Clinical Psychopharmacology 10 (Suppl. 4), 19-23. (Pubitemid 26058317)
14. Eltayb A, Wadenberg ML, Svensson TH (2005). Enhanced cortical dopamine output and antipsychotic-like effect of raclopride with adjunctive low-dose L-dopa. Biological Psychiatry 58, 337-343. (Pubitemid 41133628)
15. Ernsberger P, Giuliano R, Willette RN, Reis DJ (1990). Role of imidazole receptors in the vasodepressor response to clonidine analogs in the rostral ventrolateral medulla. Journal of Pharmacology and Experimental Therapeutics 253, 408-418. (Pubitemid 20141529)
16. Farde L, Nordström AL (1992). PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients. British Journal of Psychiatry (Suppl.) 17, 30-33.
17. Farde L, Wiesel FA, Nordström AL, Sedvall G (1989). D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology 99 (Suppl.), S28-S31. (Pubitemid 19244135)
18. Francis PT (2003). Glutamatergic systems in Alzheimers disease. International Journal of Geriatric Psychiatry 18, S15-S21.
19. Francis PT, Sims NR, Procter AW, Bowen DM (1993). Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimers disease: investigative and therapeutic perspectives. Journal of Neurochemistry 60, 1589-1604.
20. Frånberg O, Wiker C, Marcus MM, Konradsson Å , et al. (2008). Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology 196, 417-429. (Pubitemid 351200428)
21. Gelders Y, Vanden Bussche G, Reyntjens A, Janssen P (1986). Serotonin-S2 receptor blockers in the treatment of chronic schizophrenia. Clinical Neuropharmacology 9, 325-327.
22. Goldman-Rakic PS, Muly III EC, Williams GV (2000). D(1) receptors in prefrontal cells and circuits. Brain Research Brain Research Reviews 31, 295-301.
23. Green MF (1996). What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry 153, 321-330.
24. Haddjeri N, Blier P, de Montigny C (1995). Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine. International Clinical Psychopharmacology 10 (Suppl. 4), 11-17. (Pubitemid 26058316)
25. Hertel P, Fagerquist MV, Svensson TH (1999a). Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. Science 286, 105-107. (Pubitemid 29484485)
26. Hertel P, Nomikos GG, Schilstrom B, Arborelius L, Svensson TH (1997). Risperidone dose-dependently increases extracellular concentrations of serotonin in the rat frontal cortex: role of alpha 2-adrenoceptor antagonism. Neuropsychopharmacology 17, 44-55. (Pubitemid 27259712)
27. Hertel P, Nomikos GG, Svensson TH (1999b). The antipsychotic drug risperidone interacts with auto- and hetero-receptors regulating serotonin output in the rat frontal cortex. Neuropharmacology 38, 1175-1184. (Pubitemid 29292406)
28. Honey RA, Turner DC, Honey GD, Sharar SR, et al. (2003). Subdissociative dose ketamine produces a deficit in manipulation but not maintenance of the contents of working memory. Neuropsychopharmacology 28, 2037-2044.
29. Jardemark K, Ninan I, Svensson TH, Wang RY (2002). Differential effects of atypical and typical antipsychotic drugs on NMDA-receptor-mediated neurotransmission in pyramidal cells of the rat medial prefrontla cortex. Nordic Journal of Psychiatry 56, 20.
30. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia [see comments]. American Journal of Psychiatry 148, 1301-1308.
31. Kane J, Honigfeld G, Singer J, Meltzer H (1988). Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 45, 789-796.
32. Kapur S, Remington G, Zipursky RB, Wilson AA, Houle S (1995). The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sciences 57, PL103-PL107.
33. Kapur S, Zipursky RB, Remington G (1999). Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. American Journal of Psychiatry 156, 286-293. (Pubitemid 29077120)
34. Kleven SE, Assié M-B, Cosi C, Barret-Grévoz C, Newman- Tancredi A (2005). Anticataleptic properties of a2 adrenergic antagonists in the crossed leg position and bar tests: differential mediation by 5-HT1A receptor activation. Psychopharmacology 177, 373-380. (Pubitemid 40228284)
35. Konradsson A, Marcus MM, Hertel P, Svensson TH, Jardemark KE (2006). Inhibition of the glycine transporter GlyT-1 potentiates the effect of risperidone, but not clozapine, on glutamatergic transmission in the rat medial prefrontal cortex. Synapse 60, 102-108. (Pubitemid 43878118)
36. Kuroki T, Meltzer HY, Ichikawa J (1999). Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. Journal of Pharmacology and Experimental Therapeutics 288, 774-781. (Pubitemid 29119694)
37. Langlois X, te Riele P, Wintmolders C, Leysen JE, Jurzak M (2001). Use of the beta-imager for rapid ex vivo autoradiography exemplified with central nervous system penetrating neurokinin 3 antagonists. Journal of Pharmacology and Experimental Therapeutics 299, 712-717. (Pubitemid 32979686)
38. Leucht S (2009). Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373, 31-41.
39. Lewis SW, Barnes TR, Davies L, Murray RM, et al. (2006). Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophrenia Bulletin 32, 715-723. (Pubitemid 44412859)
40. Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, et al. (1988). Biochemical profile of risperidone, a new antipsychotic. Journal of Pharmacology and Experimental Therapeutics 247, 661-670.
41. Li CC (1964). Change-over design. In: Introduction to Experimental Statistics (pp. 207-226). New York: McGraw-Hill Book Company.
42. Litman RE, Hong WW, Weissman EM, Su TP, et al. (1993). Idazoxan, an alpha 2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study. Journal of Clinical Psychopharmacology 13, 264-267.
43. Litman RE, Su TP, Potter WZ, Hong WW, Pickar D (1996). Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine. British Journal of Psychiatry 168, 571-579. (Pubitemid 126425218)
44. Marcus MM, Jardemark KE, Wadenberg ML, Langlois X, et al. (2005). Combined a2 and D2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat. International Journal of Neuropsychopharmacology 8, 315-327. (Pubitemid 41002487)
45. McCormick DA, Connors BW, Lighthall JW, Prince DA (1985). Comparative electrophysiology of pyramidal and sparsely spiny stellate neurons of the neocortex. Journal of Neurophysiology 54, 782-806.
46. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, et al. (2006). Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry 163, 600-610.
47. Meltzer HY (1989). Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 99 (Suppl.), S18-S27.
48. Meltzer HY, Alphs L, Green AI, Altamura AC, et al. (2003). Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Archives of General Psychiatry 60, 82-91. (Pubitemid 36070868)
49. Meltzer HY, Matsubara S, Lee JC (1989). Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. Journal of Pharmacology and Experimental Therapeutics 251, 238-246. (Pubitemid 19261970)
50. Meltzer HY, McGurk SR (1999). The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin 25, 233-255.
51. Moghaddam B, Bunney BS (1990). Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. Journal of Neurochemistry 54, 1755-1760. (Pubitemid 20136740)
52. Murase S, Grenhoff J, Chouvet G, Gonon FG, Svensson TH (1993). Prefrontal cortex regulates burst firing and transmitter release in rat mesolimbic dopamine neurons studied in vivo. Neuroscience Letters 157, 53-56. (Pubitemid 23213054)
53. Ninan I, Jardemark KE, Wang RY (2003). Differential effects of atypical and typical antipsychotic drugs on N-methyl-Daspartate- and electrically evoked responses in the pyramidal cells of the rat medial prefrontal cortex. Synapse 48, 66-79. (Pubitemid 36374000)
54. Nomikos GG, Iurlo M, Andersson JL, Kimura K, Svensson TH (1994). Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacology 115, 147-156. (Pubitemid 24207775)
55. Nutt DJ (1994). Putting the A in atypical: does alpha2- adrenoceptor antagonism account for the therapeutic advantage of new antipsychotics? Journal of Psychopharmacology 8, 193-195.
56. Nyberg S, Eriksson B, Oxenstierna G, Halldin C, Farde L (1999). Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. American Journal of Psychiatry 156, 869-875. (Pubitemid 29260341)
57. Olsen CK, Brennum LT, Kreilgaard M (2008). Using pharmacokinetic- pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics. European Journal of Pharmacology 584, 318-327.
58. Olsen CK, Kreilgaard M, Didriksen M (2006). Positive modulation of glutamatergic receptors potentiates the suppressive effects of antipsychotics on conditioned avoidance responding in rats. Pharmacology, Biochemistry, and Behavior 84, 259-265. (Pubitemid 44107482)
59. Paxinos G, Watson C (1998). The Rat Brain in Stereotaxic Coordinates, 4th edn. San Diego: Academic Press.
60. Reyntjens A, Gelders YG, Hoppenbrouwers M-LJA, Vanden Bussche G (1986). Thymostenic effects of ritanserin (R 55667), a centrally acting serotonin-S2 receptor blocker. Drug Development Research 8, 205-211. (Pubitemid 16078139)
61. Rosenheck R, Cramer J, Xu W, Thomas J, et al. (1997). A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. New England Journal of Medicine 337, 809-815.
62. Saeedi H, Remington G, Christensen BK (2006). Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood. Schizophrenia Research 85, 222-231. (Pubitemid 43947541)
63. Salmi P, Samuelsson J, Ahlenius S (1994). A new computerassisted two-way avoidance conditioning equipment for rats: behavioral and pharmacological validation. Journal of Pharmacological and Toxicological Methods 32, 155-159. (Pubitemid 24370739)
64. Saunders RC, Kolachana BS, Bachevalier J, Weinberger DR (1998). Neonatal lesions of the medial temporal lobe disrupt prefrontal cortical regulation of striatal dopamine. Nature 393, 169-171. (Pubitemid 28242256)
65. Schilström B, Nomikos GG, Nisell M, Hertel P, Svensson TH (1998). N-methyl-D-aspartate receptor antagonism in the ventral tegmental area diminishes the systemic nicotine-induced dopamine release in the nucleus accumbens. Neuroscience 82, 781-789. (Pubitemid 27479617)
66. Schotte A, Janssen PF, Gommeren W, Luyten WH, et al. (1996). Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124, 57-73. (Pubitemid 26112775)
67. Shahid M, Walker GB, Zorn SH, Wong EH (2009). Asenapine: a novel psychopharmacologicagent with a unique human receptor signature. Journal of Psychopharmacology 23, 65-73.
68. Shannon HE, Hart JC, Bymaster FP, Calligaro DO, et al. (1999). Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats. Journal of Pharmacology and Experimental Therapeutics 290, 901-907.
69. Stone JM, Morrison PD, Pilowsky LS (2007). Glutamate and dopamine dysregulation in schizophrenia - a synthesis and selective review. Journal of Psychopharmacology 21, 440-452.
70. Svensson TH (2003). Preclinical effects of conventional and atypical antipsychotic drugs: defining the mechanisms of action. Clinical Neuroscience Research 3, 34-46.
71. Swartz MS, Stroup TS, McEvoy JP, Davis SM, et al. (2008). What CATIE found: results from the schizophrenia trial. Psychiatric Services 59, 500-506.
72. Tan HY, Callicott JH, Weinberger DR (2007). Dysfunctional and compensatory prefrontal cortical systems, genes and the pathogenesis of schizophrenia. Cerebral Cortex 17 (Suppl. 1), i171-i181.
73. Wadenberg ML, Ericson E, Magnusson O, Ahlenius S (1990). Suppression of conditioned avoidance behavior by the local application of (-)sulpiride into the ventral, but not the dorsal, striatum of the rat. Biological Psychiatry 28, 297-307. (Pubitemid 20253246)
74. Wadenberg ML, Hicks PB (1999). The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? Neuroscience and Biobehavioral Reviews 23, 851-862.
75. Wadenberg ML, Salmi P, Jimenez P, Svensson T, Ahlenius S (1996). Enhancement of antipsychotic-like properties of the dopamine D2 receptor antagonist, raclopride, by the additional treatment with the 5-HT2 receptor blocking agent, ritanserin, in the rat. European Neuropsychopharmacology 6, 305-310. (Pubitemid 26422791)
76. Wadenberg ML, Wiker C, Svensson TH (2007). Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive alpha2 adrenoceptor blockade: experimental evidence. International Journal of Neuropsychopharmacology 10, 191-202. (Pubitemid 46270994)
77. Wadenberg M-LG, Soliman A, VanderSpek SC, Kapur S (2001). Dopamine d(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 25, 633-641. (Pubitemid 32995945)
78. Weinberger DR, Egan MF, Bertolino A, Callicott JH, et al. (2001). Prefrontal neurons and the genetics of schizophrenia. Biological Psychiatry 50, 825-844. (Pubitemid 34020697)